As of 2026-04-09, the EV/EBITDA ratio of Chinook Therapeutics Inc (KDNY) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KDNY's latest enterprise value is 2,773.05 mil USD. KDNY's TTM EBITDA according to its financial statements is -233.23 mil USD. Dividing these 2 quantities gives us the above KDNY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.1x | 14.2x |
| Forward P/E multiples | 15.6x - 19.7x | 17.8x |
| Fair Price | (48.84) - (47.21) | (50.12) |
| Upside | -220.9% - -216.9% | -224.1% |
| Date | EV/EBITDA |